InMode Ltd (NASDAQ:INMD) Reports Mixed Q2 2025 Results: Revenue Miss but EPS Beat Drives Pre-Market Gains

InMode Ltd (NASDAQ:INMD) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company posted revenue of $95.6 million, falling short of the consensus estimate of $99.3 million. However, earnings per share (EPS) came in at $0.47, surpassing the projected $0.42. The market reaction has been cautiously positive, with shares rising approximately 3.4% in pre-market trading following the announcement.

Key Takeaways from the Earnings Report

• Revenue Miss: InMode’s Q2 revenue of $95.6 million was about 3.7% below analyst expectations, marking a potential slowdown in sales growth.
• Strong Profitability: Despite the revenue shortfall, the company maintained an impressive 80% gross margin, contributing to higher-than-expected EPS.
• Market Reaction: The pre-market uptick suggests investors are focusing more on profitability than the top-line miss, though the stock’s weekly performance remains nearly flat (-0.7%).

Comparing Estimates and Performance

While InMode’s revenue growth appears to be decelerating slightly, its ability to convert sales into earnings remains robust. The beat on EPS indicates disciplined cost management, a factor that may reassure shareholders even as revenue growth moderates.

Looking ahead, analysts expect Q3 2025 revenue of $92.8 million and full-year sales of $395.4 million. The company did not provide an official outlook in its press release, leaving investors to rely on external estimates for forward guidance.

Broader Context

InMode specializes in minimally invasive aesthetic medical technologies, leveraging radiofrequency (RF) energy for procedures like fat reduction and skin tightening. Its high-margin business model has historically attracted investor interest, though any sustained revenue underperformance could raise concerns about market saturation or competitive pressures.

For a deeper dive into InMode’s earnings history and future estimates, see the full earnings and estimates breakdown.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.